Fertility Preservation in AYA Cancer Patients

Prof Raymond Chan

Professor – Cancer Nursing, Metro South Health and Queensland University of Technology





Fertility Preservation Options

Fertility preservation options for girls and young women:


- Embryo cryopreservation
- Ovarian transposition
- Experimental freezing mature oocytes (2-3% success rate)
- Experimental gonadal protection GnRHa (conflicting evidence)
- Experimental ovarian tissue cryopreservation***

Fertility preservation options for boys and young men:

- Semen collection and storage potential surgical semen extraction
- Testicular biopsy with freezing of testicular tissue or spermatozoa retrieved from the tissue.



Focus of this Presentation





Fertility Preservation in AYA Cancer Patients

- Health professionals' and health services' responses to the needs of cancer survivors
- Implementation research in cancer survivorship





ASCO Guidelines Bottom Line (2018 Update)

Role of Health Care Providers

Recommendation 4.1: All oncologic health care providers <u>should be prepared</u> to discuss infertility as a potential risk of therapy (<u>as soon as possible once a cancer diagnosis is</u> <u>made</u>).

Recommendation 4.3: <u>Refer</u> patients who express an interest in fertility, as well as those who are ambivalent or uncertain, <u>to reproductive specialists</u> as soon as possible.

Recommendation 4.4: Refer patients to psychosocial providers when they are discussed about potential infertility.



COSA Guidelines

COSA Guidelines AYA Cancer Fertility Preservation (2014):

- Many young people report feeling that:
 - They were not, or were inadequately, advised of the risk or their options for preserving fertility.
 - The decision about whether to pursue fertility preservation or not was made for them
 - They were not given enough time to discuss concerns
 - They did not fully understand the ramifications of the decision.

Lee et al, JCO, 2006; Achille et al Hum Reprod 2006; Crawshaw et al Eur J Cancer Care 2009

COSA 2014





Oncology Practitioners Perspective and Practices

Chan et al. BMC Cancer (2017) 17:715 DOI 10.1186/s12885-017-3733-3

BMC Cancer

RESEARCH ARTICLE

Open Access




Oncology practitioners' perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: results from the STEP study

Raymond Javan Chan^{1,2*}, Patsy Yates^{1,2}, Qiuping Li³, Hiroko Komatsu⁴, Violeta Lopez⁵, Myat Thandar⁶, Selva Titus Chacko⁷, Winnie Kwok Wei So⁸, Kanaungnit Pongthavornkamol⁹, Myungsun Yi¹⁰, Pongpak Pittayapan¹¹, Jessica Butcon¹², David Wyld², Alex Molassiotis¹³ and on behalf of the STEP study collaborators



Oncology Practitioners Perspective and Practices in the APAC Region (n=1,501)


• Should *discussing fertility options and issues* be part of your role?





Oncology Practitioners Perspective and Practices in the APAC Region (n=1,501)


• How confident are you in *discussing fertility issues and* options? Mean (SD) =5.69 (3.05)





Oncology Practitioners Perspective and Practices in the APAC Region (n=1,501)


• How frequently do you *discuss fertility options and issues* in your practice?





Preparedness of Australian Oncology Health Professionals

Youth Cancer Services- Queensland Survey of Health Professional Educational Needs (2013- *n*=122; 2017- *n*=73)



43% Nursing staff 10% Medical staff 46% Allied Health



Bradford,... Henney (2018) J Adolesc Young Adult Oncol



Implementation Study



Aim: To improve documented discussion about risk of infertility and fertility preservation options

Population: AYA patients aged 14-25 years at the time of a cancer diagnosis during 2012-2014/2015-2016

Intervention:

• Year 2015

Data collection periods:

- Pre-test: 2012-2014 (Medical Records)
- Post-test: 2015-2016 (QOOL Data)



Five Major Cancer Centres



Tertiary Metro Queensland, Australia:

- Lady Cilento Children's Hospital
- Royal Brisbane and Women's Hospital
- Princess Alexandra Hospital

Tertiary Regional Queensland, Australia:

- Townsville Hospital
- Gold Coast University Hospital






Bundled Intervention



- Development of Quality Indicators
 - Prospectively collected and entered into QOOL for all patients referred to Youth Cancer Services → regular feedback to clinicians
- Targeted Education
 - For clinicians at across cancer centres
- Patient Resources
 - Gender-specific patient resource packs for newly diagnosed patients
- Referral Pathways
 - Pathways, procedure and work instruction forms











Variable		Pre-intervention (2012-2014) N=260 %		ntervention 15-2016) =216 %	Chi square <i>p</i> value	
Age at diagnosis						
14-19	121	47%	102	47%	n-0.0 C	
20-25	139	53%	114	53%	p=0.96	
Gender						
Male	153	59%	128	59%	-0.02	
Female	107	41%	88	41%	p=0.93	
Cancer Diagnosis						
Leukaemia	50	19%	39	18%		
Lymphoma	60	23%	63	29%		
Brain cancer	35	13%	23	11%		
Bone sarcoma	26	10%	27	13%	2-0.46	
Soft tissue sarcoma	18	7%	18	8%	p=0.46	
Germ cell tumour	37	14%	29	13%		
Carcinoma	24	9%	13	6%		
Other	10	4%	4	2%		
Type of treatment						
Multimodal	108	42%	96	44%		
Chemotherapy only	104	40%	102	47%	p=0.006	
Surgery +/-localised radiotherapy	48	18%	18	8%		
Toxicity of treatment on gonads						
Intermediate to high risk	195	75%	168	78%	-0 FF	
Low to no risk	65	25%	48	22%	p=0.55	








Variable	Pre intervention N=260 (%)	Post intervention N=216 (%)	Chi-square p value				
Evidence risk of infertility discussion							
Yes No	159 (61%) 101 (39%)	194 (89%) 22 (11%)	<i>p</i> <0.001				
Documented fertility preservation outcomes							
Yes No	93 (36%) 167 (64%)	100 (46%) 116 (54%)	<i>p</i> =0.02				

Significant Improvements observed in post-intervention data collection:

Evidence of risk of infertility discussion (RR 1.47 95%CI: 1.12-1.63, *p*<0.001) Documented referrals to fertility specialist (RR 1.53, 95%CI: 1.26-1.87, *p*<0.001) Documented fertility preservation outcomes (RR 2.56, 95%CI: 1.19-3.44, *p*<0.001)





Results – Documented Discussion



TABLE 2. DOCUMENTED RISK OF INFERTILITY DISCUSSION BY GENDER, AGE, AND DISEASE PRE-INTERVENTION (N=260) and Post-intervention (N=216)

Variable	Pre-intervention		Post-intervention			
	n/total n	%	n/total n	%	RR (95% CI)	р
Gender						
Males	104/153	68	117/128	91	1.35(1.19-1.5)	< 0.001
Females	55/107	51	77/88	88	1.70 (1.39-2.08)	< 0.001
Age group						
14-19 years	72/121	60	88/102	86	1.45(1.22 - 1.71)	< 0.001
20-25 years	87/139	63	106/114	93	1.48 (1.29-1.70)	< 0.001
Disease						
Leukemia	35/50	70	36/39	92	1.32 (1.07-1.62)	0.008
Lymphoma	48/60	80	59/63	94	1.27(0.99 - 1.63)	0.06
Brain cancer	12/35	34	17/23	74	2.15 (1.03-3.62)	0.004
Bone sarcoma	19/26	73	26/27	96	1.32 (1.03-1.69)	0.03
Soft tissue sarcoma	5/18	28	13/18	72	2.60(1.17 - 5.78)	0.02
Germ cell tumor	24/37	65	28/29	97	1.49 (1.16-1.91)	0.002
Carcinoma	14/24	58	12/13	92	1.58 (1.09-2.30)	0.02
Other	2/10	20	3/4	75	3.75 (0.96-14.65)	0.06
All patients	159/260	61	194/216	90	1.47 (1.12-1.63)	< 0.001

RR, relative risk; CI, confidence intervals.



Results - Documented Preservation

TABLE 4. DOCUMENTED OUTCOMES OF FERTILITY PRESERVATION BY GENDER, AGE, AND DISEASE, PRE-INTERVENTIONS (N=260) AND POST-INTERVENTION (N=216)

Variable	Pre-intervention		Post-intervention			
	n∕total n	%	n/total n	%	RR (95% CI)	р
Gender						
Males	31/153	20	75/128	59	2.89 (2.05-4.09)	< 0.001
Females	16/107	15	25/88	28	1.90 (1.08-3.33)	0.0025
Age group						
14-19 years	17/121	14	26/92	28	2.01 (1.16-3.48)	0.025
20-25 years	30/139	22	64/114	54	2.60 (1.82-3.71)	< 0.001
Disease						
Leukemia	10/50	20	14/39	36	1.43 (0.70-2.90)	0.32
Lymphoma	15/60	25	34/63	54	2.16 (1.32-3.54)	0.002
Brain cancer	5/35	14	7/23	30	2.13 (0.77-5.91)	0.15
Bone sarcoma	5/26	19	16/27	59	3.08 (1.32-7.18)	0.009
Soft tissue sarcoma	1/18	6	5/18	28	5.00 (0.66-38.65)	0.12
Germ cell tumor	8/37	22	17/29	59	2.71 (1.37-5.38)	0.004
Carcinoma	3/24	13	6/13	46	3.69 (1.10-12.39)	0.03
Other	0/10		1/4	25	6.60 (0.32-135.38)	0.22
All patients	47/260	18	100/216	46	2.56 (1.19-3.44)	< 0.001



Results – Variables Associated wit Documented Preservation Outcomes

TABLE 5. POST-INTERVENTION COHORT, COMPARISON OF VARIABLES ASSOCIATED WITH DOCUMENTED FERTILITY PRESERVATION OUTCOMES (N=216)

		Documented out			
Variable	Yes	%	No	%	<i>RR</i> ^a (95% <i>CI</i>); p
Age group at diagnosis	145-7		1000	0.275	
14-19	26	28 56	76 50	72	0.50 (0.35-0.72); 0.0002
20-25	64	56	50	72 44	
Gender					
Male	75	59	53	41	2.06 (1.44-2.96); 0.0001
Female	75 25	28	63	41 72	
Cancer diagnosis					
Leukemia	14	36	25	64	0.74 (0.47-1.15); 0.18
Lymphomas	34 7	36 54	29	46	1.25 (0.93-1.67); 0.13
Brain cancers	7	30	16	70	0.63 (0.33-1.18); 0.16
Bone sarcomas	16	59	11	41	1.33 (0.94-1.89); 0.11
Soft tissue sarcomas	5 17	28	13	72	0.52 (0.24-1.13); 0.09
Germ cell tumors	17	28 59	12	41 72 41	1.32 (0.94-1.87); 0.11
Carcinomas	6	46 25	7	54	0.99 (0.54-1.83); 0.99
Other	1	25	3	75	0.53 (0.09-2.9); 0.47

^aFourteen to 19 compared to 20-25 years, males compared to females, each disease compared to sum of all other diseases.







- Retrospective nature of the pre-intervention cohort (reliance on medical records)
- Pre- and post- data collection sources were different (medical records vs a prospective data reporting mechanism)
- Nevertheless, documentation is extremely important in survivorship care practices. Failure to document impedes future clinical interventions and may have medico-legal consequences



Discussion

- The disparities between gender and disease groups were closed to a certain extent with the introduction of interventions
- We were not able to demonstrate improvements in documented <u>referrals to specialists</u> and <u>outcomes of</u> <u>fertility preservation</u> in leukaemia patients
- Implementation research (quality improvement studies) should be afforded in the local context to enhance guidelines driven care
- The field of ovarian tissue cryopreservation is advancing quickly and will continue to evolve *health professionals should pay notice to new evidence-based guidelines*





Email: <u>Raymond.Chan@qut.edu.au</u>

